Stay informed with free updates
Simply sign up to the GSK PLC myFT Digest — delivered directly to your inbox.
GSK has signed a deal with China’s largest vaccine company by revenue Zhifei, as the British drugmaker aims to double global sales of its shingles vaccine by 2026.
The UK-based pharmaceutical company said Zhifei had agreed to buy £2.5bn worth of GSK’s bestselling shot Shingrix, which is targeted at older adults, over three years.
The deal includes an option for Zhifei to also distribute GSK’s vaccine for respiratory syncytial virus (RSV) if it is approved by regulators in China.
The partnership is the first of its kind in China for GSK but Zhifei has previously partnered with Merck to sell its vaccines in the country.
